NASDAQ: IKT - Inhibikase Therapeutics, Inc.

半年間の収益性: +152.07%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Inhibikase Therapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc.

さらに詳しく
has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2020-12-23
ISIN US45719W1062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.inhibikase.com
Цена ао 2.29
1日あたりの価格変動: -0.3268% (3.06)
週ごとの価格変動: -4.69% (3.2)
月ごとの料金変更: +11.72% (2.73)
3ヶ月間の価格変動: +160.68% (1.17)
半年間の価格変動: +152.07% (1.21)
年間の価格変動: +140.16% (1.27)
3年間の価格推移: +87.12% (1.63)
5年間の価格推移: 0% (3.05)
10年間の価格推移: 0% (3.05)
年初からの価格変動: +51.74% (2.01)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 25.18 1
P/BV 0.5975 10
P/E 0 0
EV/EBITDA 0.0996 10
合計: 5.13

効率

名前 意味 学年
ROA, % -131.17 0
ROE, % -173.34 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0312 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -76.32 0
収益性 Ebitda, % 249.34 10
収益性 EPS, % 3.72 1
合計: 6.2
さらに詳しく

機関 音量 共有, %
Armistice Capital, LLC 186046 3.01
Vanguard Group Inc 87447 1.42
Blair (William) & Company, L.L.C. 59375 0.96
Geode Capital Management, LLC 28692 0.46
Redmond Asset Management, LLC 20977 0.34
Edgewood Management Llc 16666 0.27
Renaissance Technologies, LLC 16122 0.26
State Street Corporation 10084 0.16
Tower Research Capital LLC (TRC) 2200 0.04
Morgan Stanley 1667 0.03



スーパーバイザー 役職 支払い 生年
Dr. Milton H. Werner Ph.D. CEO, President & Director 697.96k 1964 (61 年)
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls N/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. CEO of Clintrex Research Corporation & Member of Scientific Advisory Board N/A
Dan Williams Controller N/A
Mr. Garth Lees-Rolfe CPA Chief Financial Officer N/A 1985 (40 年)

住所: United States, Atlanta. GA, 3350 Riverwood Parkway SE - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.inhibikase.com